Abstract 1945 Poster Session II, Sunday, 5/2 (poster 174)

There has been marked improvement in the past decade of graft and patient survival in the pediatric renal transplant population. A major contributor to this success has been improved immunosuppressive drugs. Approximately one-third of patients continue to have difficulty with recurrent rejections/chronic rejection, allograft nephropathy, or drug toxicity. Thirty-five pediatric patients have had renal transplantation at the IWK∼Grace Health Centre over the past 5 years. We developed criteria for switching patients from baseline Cyclosporin A (CyA) to FK506: (1) 2 or more biopsy-proven rejections in less than 3 years, (2) biopsy-proven CyA toxicity, and (3) patient concerns regarding CyA ± non-compliance, (4) significant facial morphology changes on CyA, and (5) primary diseases aggravated by CyA.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD